|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2011-3-7
|
|
pubmed:abstractText |
Effective and selective treatment options are needed for patients with colorectal cancer (CRC). The CD24 mucin-like glycoprotein is overexpressed in CRCs; monoclonal antibodies (mAbs) against CD24 inhibit tumor cell growth in vitro and in vivo. Based on the tumor-specific expression of CD24, we investigated the potential of anti-CD24 SWA11 mAb, to deliver a cytotoxic agent into CRC cells.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/ADP Ribose Transferases,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD24,
http://linkedlifedata.com/resource/pubmed/chemical/Bacterial Toxins,
http://linkedlifedata.com/resource/pubmed/chemical/CD24 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Exotoxins,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoconjugates,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Staphylococcal Protein A,
http://linkedlifedata.com/resource/pubmed/chemical/Virulence Factors,
http://linkedlifedata.com/resource/pubmed/chemical/toxA protein, Pseudomonas aeruginosa
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1528-0012
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
140
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
935-46
|
|
pubmed:meshHeading |
pubmed-meshheading:21147107-ADP Ribose Transferases,
pubmed-meshheading:21147107-Animals,
pubmed-meshheading:21147107-Antibodies, Monoclonal,
pubmed-meshheading:21147107-Antigens, CD24,
pubmed-meshheading:21147107-Apoptosis,
pubmed-meshheading:21147107-Bacterial Toxins,
pubmed-meshheading:21147107-Cell Proliferation,
pubmed-meshheading:21147107-Cell Survival,
pubmed-meshheading:21147107-Colorectal Neoplasms,
pubmed-meshheading:21147107-Dose-Response Relationship, Drug,
pubmed-meshheading:21147107-Exotoxins,
pubmed-meshheading:21147107-HCT116 Cells,
pubmed-meshheading:21147107-HT29 Cells,
pubmed-meshheading:21147107-Humans,
pubmed-meshheading:21147107-Immunoconjugates,
pubmed-meshheading:21147107-Inhibitory Concentration 50,
pubmed-meshheading:21147107-Mice,
pubmed-meshheading:21147107-Mice, Nude,
pubmed-meshheading:21147107-Recombinant Fusion Proteins,
pubmed-meshheading:21147107-Staphylococcal Protein A,
pubmed-meshheading:21147107-Time Factors,
pubmed-meshheading:21147107-Tumor Burden,
pubmed-meshheading:21147107-Virulence Factors,
pubmed-meshheading:21147107-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
An immunoconjugate of anti-CD24 and Pseudomonas exotoxin selectively kills human colorectal tumors in mice.
|
|
pubmed:affiliation |
The Integrated Cancer Prevention Center, Tel Aviv, Israel.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
